Introduction
Artificial intelligence (AI) technologies are reshaping the pharmaceutical R&D landscape, especially in the realms of drug discovery, clinical trial design, and biomedical data analysis. Machine learning algorithms are increasingly used to accelerate research timelines, reduce costs, and optimize clinical success rates.
However, these systems also introduce new types of risk. Errors such as biased data sets, incorrect predictions, or opaque decision-making may lead to misleading trial outcomes, compromising both patient safety and regulatory compliance. This raises critical legal questions about responsibility, causation, liability, and informed consent in the age of algorithm-driven drug development.
1. The Role of AI in Drug Discovery
AI systems are employed in multiple stages of pharmaceutical research, including:
- Target identification and validation,
- De novo drug design,
- Candidate molecule screening,
- Patient stratification and subgroup analysis,
- Adverse effect and toxicity prediction.
Most of these models are based on deep learning architectures trained on large biomedical data sets. Despite their power, these models often operate as black-box systems—meaning their decision-making process lacks transparency and is difficult to audit.
2. Algorithmic Errors in Clinical Trials: Potential Scenarios
AI-driven tools used in clinical trials may lead to several types of errors:
- Flawed patient selection algorithms: Poorly trained models may select inappropriate risk groups.
- Incorrect dose-response predictions: Inaccurate toxicity thresholds may result in adverse effects.
- Data bias: Certain demographics may be excluded or underrepresented in training data.
- Misclassification of trial phases: AI may inaccurately report clinical benefits or harm.
These outcomes could invalidate trial results, lead to unsafe drug approvals, or cause harm to trial participants.
3. Legal Liability: Who Is Responsible?
When an algorithmic error results in harm, determining legal liability becomes complex.
⚖️ Possible liable parties include:
- The sponsor (pharmaceutical company): Ultimately responsible for the clinical trial’s outcomes.
- AI software developer: If the algorithm itself is defective, product liability or software negligence may apply.
- Clinical researchers or investigators: If they relied uncritically on AI decisions, professional liability may arise.
- Ethics committees: If they failed to evaluate the algorithm’s risks, secondary liability could be argued.
Liability may arise under various legal frameworks:
- Contractual liability (e.g., between sponsor and AI provider),
- Tort liability (for harm caused to trial subjects),
- Professional malpractice (for clinical staff),
- Product liability (for faulty AI systems).
4. Regulatory and Legal Framework
In Turkey:
- The Regulation on Clinical Trials places primary responsibility on the sponsor for all aspects of the trial.
- The KVKK (Personal Data Protection Law) governs lawful processing of health data by AI systems.
- The Turkish Medicines and Medical Devices Agency (TİTCK) oversees the approval of AI-powered clinical tools.
At the international level:
- The EU AI Act classifies medical AI systems as “high-risk” and subject to strict oversight.
- The FDA in the U.S. regulates such tools under the Software as a Medical Device (SaMD) framework.
5. Ethical Oversight and Algorithmic Transparency
Due to the unpredictable nature of AI decisions, ethics committees play a more vital role than ever. They must evaluate:
- The AI model’s architecture,
- The origin of training datasets,
- The validation and testing process.
Full transparency must be ensured to uphold patient rights and informed consent. In the case of black-box models, whether informed consent is truly “informed” becomes a pressing ethical and legal concern.
Conclusion
AI-assisted drug discovery represents a paradigm shift in pharmaceutical development. However, its adoption must be matched by robust legal and ethical frameworks.
Algorithmic errors may:
- Harm clinical trial volunteers,
- Compromise scientific validity,
- Lead to unsafe or ineffective drugs entering the market.
Therefore:
🔹 The chain of responsibility must be clearly defined.
🔹 Contracts between sponsors and AI providers must explicitly address liability.
🔹 Ethics committees must gain competence in assessing AI systems.
🔹 AI tools must undergo not only technical validation but also legal and ethical certification.
Yanıt yok